
JAK
JAK (Janus kinase) inhibitors are compounds that target the JAK-STAT signaling pathway, which is involved in cell growth, immune response, and angiogenesis. By inhibiting JAK, these compounds can reduce the signaling that leads to the formation of new blood vessels in tumors, thereby inhibiting tumor growth. JAK inhibitors are important in the treatment of cancers and inflammatory diseases. At CymitQuimica, we offer a diverse range of high-quality JAK inhibitors to support your research in oncology, immunology, and angiogenesis.
Products of "JAK"
Sort by
AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Formula:C29H28F3N5O2Purity:98%Color and Shape:SolidMolecular weight:535.56Ruxolitinib
CAS:Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.Formula:C17H18N6Purity:100% - 99.99%Color and Shape:SolidMolecular weight:306.36Ref: TM-T1829
5mg58.00€10mg74.00€25mg92.00€50mg116.00€100mg155.00€200mg245.00€500mg414.00€1mL*10mM (DMSO)65.00€SHR0302
CAS:SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,Formula:C18H22N8O2SPurity:99.11%Color and Shape:SolidMolecular weight:414.48Ref: TM-T9195
1mg160.00€5mg393.00€10mg620.00€25mg1,035.00€50mg1,483.00€100mg1,882.00€1mL*10mM (DMSO)455.00€lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Formula:C16H25N5OSColor and Shape:SolidMolecular weight:335.468JAK-IN-11
CAS:JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.Formula:C23H22FN5O4SPurity:99.57%Color and Shape:SolidMolecular weight:483.52Tofacitinib
CAS:Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.Formula:C16H20N6OPurity:100% - 99.71%Color and Shape:SolidMolecular weight:312.37JAK1/STAT3-IN-1
JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).Formula:C30H33FN4O3SColor and Shape:SolidMolecular weight:548.67AZD-1480
CAS:AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.Formula:C14H14ClFN8Purity:97.5% - 98.55%Color and Shape:SolidMolecular weight:348.77TG101209
CAS:TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.Formula:C26H35N7O2SPurity:100% - 99.36%Color and Shape:SolidMolecular weight:509.67JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nMFormula:C20H21F2N7OPurity:98%Color and Shape:SolidMolecular weight:413.42JAK2-IN-11
CAS:JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with potent antitumor activity, exhibiting an IC50 of ≤10 nM against JH2 BIND WT/V617F. This compound effectively suppresses tumor growth.Formula:C31H31F3N8O4Color and Shape:SolidMolecular weight:639.64Fedratinib
CAS:Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.Formula:C27H36N6O3SPurity:98.23% - 99.96%Color and Shape:SolidMolecular weight:524.68Ref: TM-T1995
1g625.00€5mg49.00€10mg69.00€50mg113.00€100mg134.00€200mg216.00€500mg472.00€1mL*10mM (DMSO)57.00€Pyridone 6
CAS:Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).Formula:C18H16FN3OPurity:97.10% - 98.74%Color and Shape:SolidMolecular weight:309.34Ref: TM-T3080
1mg82.00€2mg106.00€5mg162.00€10mg221.00€25mg449.00€50mg658.00€100mg939.00€500mg1,882.00€1mL*10mM (DMSO)177.00€Baricitinib
CAS:Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.Formula:C16H17N7O2SPurity:100% - 99.79%Color and Shape:SolidMolecular weight:371.42Ref: TM-T2485
5mg50.00€10mg73.00€25mg90.00€50mg115.00€100mg144.00€200mg188.00€500mg311.00€1mL*10mM (DMSO)69.00€JAK1-IN-4
CAS:JAK1-IN-4 selectively blocks JAK1 (IC50 = 85 nM) over JAK2/JAK3 and halts STAT3 phosphorylation in NCI-H 1975 cells (IC50 = 227 nM).Formula:C26H32FN9O2Purity:98%Color and Shape:SolidMolecular weight:521.59Filgotinib
CAS:Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.Formula:C21H23N5O3SPurity:98.03% - ≥95%Color and Shape:SolidMolecular weight:425.5JAK2 Inhibitor V
CAS:JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.Formula:C23H24N2OPurity:96.69% - 99.15%Color and Shape:SolidMolecular weight:344.45Ref: TM-T3042
2mg39.00€5mg57.00€10mg85.00€25mg157.00€50mg274.00€100mg505.00€500mg1,121.00€1mL*10mM (DMSO)63.00€DPP
CAS:DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstratingFormula:C36H40Cl2N2O10PtPurity:98%Color and Shape:SolidMolecular weight:926.7AJI-100
CAS:AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32